<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056472</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH062624</org_study_id>
    <secondary_id>U01MH062624</secondary_id>
    <secondary_id>U01MH062565</secondary_id>
    <secondary_id>U01MH062518</secondary_id>
    <secondary_id>U01MH062446</secondary_id>
    <nct_id>NCT00056472</nct_id>
  </id_info>
  <brief_title>Study of Pharmacotherapy of Psychotic Depression</brief_title>
  <acronym>STOP-PD</acronym>
  <official_title>Effectiveness of Selective Serotonin Reuptake Inhibitors Combined With Antipsychotic Medication for the Treatment of Psychotic Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of combining selective serotonin reuptake
      inhibitors (SSRIs) with antipsychotic medications in the treatment of psychotic depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 25% of people who are admitted to hospitals for depression suffer from
      psychotic depression. People with psychotic depression experience hallucinations,and, more
      commonly delusions, in addition to major depression. Psychotic experiences may be either
      congruent with the theme of depression or incongruent, without an apparent relationship to
      feeling depressed. This study will determine the effectiveness of combining a selective
      serotonin reuptake inhibitor (SSRI) with antipsychotic medication in the treatment of
      psychotic depression accompanied by at least one identifiable delusion. The study will also
      evaluate the difference in treatment response of young adults versus geriatric patients.

      This double-blind study will last a total of 12 weeks. Participants will be randomly assigned
      to receive either olanzapine, an atypical antipsychotic drug, combined with sertraline, an
      SSRI, or olanzapine alone. Following baseline assessments, study visits will occur weekly
      until Week 6, and then bi-weekly until Week 12. Participants who do not respond to either
      treatment may leave the study at any time. Participants who achieve either partial or full
      response may participate in an additional 20-week study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial</measure>
    <time_frame>Weeks 1 to 12</time_frame>
    <description>Remission was defined as scores on Ham-D of less than 10 at two consecutive assessments and the absence of delusions (measured as SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval.
Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression. Scores on SADS range from 1 to 7 with higher scores indicating the delusions(s) more adversely effect the subject's behavior.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scores on CGI-S Compared to Baseline Over the Course of the Trial</measure>
    <time_frame>Weeks 1 to 12</time_frame>
    <description>A measure of overall symptom severity, the Clinical Global Impressions, Severity of Illness Scale (CGI-S). It is a seven point scale with a one indicating not at all ill, and seven indicating the most extremely ill. This rating was done each week after baseline by the PI at each site after visiting with the patient.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week.</measure>
    <time_frame>Weeks 1 to 12</time_frame>
    <description>The Ham-D measures depression severity. Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">259</enrollment>
  <condition>Major Depressive Disorder With Psychotic Features</condition>
  <arm_group>
    <arm_group_label>olanzapine/sertraline combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sertraline plus olanzapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>olanzapine (5 - 20mg/day) plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>10-20mg/day</description>
    <arm_group_label>olanzapine/sertraline combination</arm_group_label>
    <arm_group_label>olanzapine plus placebo</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>150-200mg/day</description>
    <arm_group_label>olanzapine/sertraline combination</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet that ressembles sertraline but contains no medication</description>
    <arm_group_label>olanzapine plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major depressive disorder, single or recurrent, with psychotic features

        Exclusion Criteria:

          -  History of substance abuse or dependence within the 3 months prior to enrollment

          -  Acute or unstable medical illness

          -  Diagnosis of schizophrenia or other psychotic disorders

          -  Pregnant

          -  Intolerance to SSRIs or olanzapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnett Meyers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2003</study_first_submitted>
  <study_first_submitted_qc>March 14, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2003</study_first_posted>
  <results_first_submitted>June 16, 2009</results_first_submitted>
  <results_first_submitted_qc>June 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2013</results_first_posted>
  <last_update_submitted>June 26, 2013</last_update_submitted>
  <last_update_submitted_qc>June 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major depressive disorder with psychotic features</keyword>
  <keyword>Delusional Depression</keyword>
  <keyword>Randomized Trial</keyword>
  <keyword>Combination Treatment</keyword>
  <keyword>SSRI</keyword>
  <keyword>Atypical Antipsychotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the inpatient and outpatient services of four academic sites between December of 2002 and June of 2007.</recruitment_details>
      <pre_assignment_details>Antidepressant and antipsychotic medications being taken at entry were tapered and discontinued prior to randomization. Consented subjects were required to meet criteria for unipolar major depression and have at least one delusion. Subjects were also excluded if an unstable medical condition or evidence of recent substance abuse were present.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertraline Plus Olanzapine</title>
          <description>50-200mg/day sertraline plus 5-20mg/day olanzapine</description>
        </group>
        <group group_id="P2">
          <title>Olanzapine Plus Placebo</title>
          <description>5-20mg/day olanzapine plus placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pharmacotherapy</title>
          <description>sertraline plus olanzapine</description>
        </group>
        <group group_id="B2">
          <title>Monotherapy</title>
          <description>placebo plus olanzapine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial</title>
        <description>Remission was defined as scores on Ham-D of less than 10 at two consecutive assessments and the absence of delusions (measured as SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval.
Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression. Scores on SADS range from 1 to 7 with higher scores indicating the delusions(s) more adversely effect the subject's behavior.</description>
        <time_frame>Weeks 1 to 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy</title>
            <description>sertraline plus olanzapine</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>placebo plus olanzapine</description>
          </group>
        </group_list>
        <measure>
          <title>Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial</title>
          <description>Remission was defined as scores on Ham-D of less than 10 at two consecutive assessments and the absence of delusions (measured as SADS delusional item scores of 1) at the second assessment of the two-assessment remission of depression interval.
Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression. Scores on SADS range from 1 to 7 with higher scores indicating the delusions(s) more adversely effect the subject's behavior.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Predicting remission rates of 40% in combination therapy and 20% in monotherapy subjects, 260 subjects randomized into the two treatment groups would provide &gt;80% power at a two-tailed alpha level of .05. Treatment efficacy was compared between groups based on intent-to-treat analyses for the longitudinal binary outcome of remission using mixed effects logistic regression with a random intercept that included treatment and time as fixed effects and a treatment by time interaction effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scores on CGI-S Compared to Baseline Over the Course of the Trial</title>
        <description>A measure of overall symptom severity, the Clinical Global Impressions, Severity of Illness Scale (CGI-S). It is a seven point scale with a one indicating not at all ill, and seven indicating the most extremely ill. This rating was done each week after baseline by the PI at each site after visiting with the patient.</description>
        <time_frame>Weeks 1 to 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy</title>
            <description>sertraline plus olanzapine</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>placebo plus olanzapine</description>
          </group>
        </group_list>
        <measure>
          <title>Scores on CGI-S Compared to Baseline Over the Course of the Trial</title>
          <description>A measure of overall symptom severity, the Clinical Global Impressions, Severity of Illness Scale (CGI-S). It is a seven point scale with a one indicating not at all ill, and seven indicating the most extremely ill. This rating was done each week after baseline by the PI at each site after visiting with the patient.</description>
          <units>units on CGI scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread=".07"/>
                    <measurement group_id="O2" value="2.48" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent-to-treat changes in global improvement from week to week compared to baseline (CGI-S) over the course of the trial using longitudinal mixed effects linear regression models. The null hypothesis is that there is no difference in overall change in CGI-S.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.02</p_value>
            <p_value_desc>The p-value is for the overall mean CGI-S score compared to baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>This was a longitudinal analysis of CGI-S scores compared to baseline.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week.</title>
        <description>The Ham-D measures depression severity. Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression.</description>
        <time_frame>Weeks 1 to 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pharmacotherapy</title>
            <description>sertraline plus olanzapine</description>
          </group>
          <group group_id="O2">
            <title>Monotherapy</title>
            <description>placebo plus olanzapine</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Score Hamilton Depression Rating Scale (Ham-D) Over the Course of the Trial From Week to Week.</title>
          <description>The Ham-D measures depression severity. Scores on Ham-D range from 0 to 52 with higher scores indicating more severe depression.</description>
          <units>Scores on Ham-D</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.27" spread=".61"/>
                    <measurement group_id="O2" value="16.63" spread=".61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Intent-to-treat between group comparison using longitudinal mixed effects regression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>The p-value is for the overall mean across all time points between each treatment group.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects participated for a maximum of 12 weeks. Study duration of 4.5 years</time_frame>
      <desc>Extrapyramidal symptoms assessed using the Simpson Angus Scale, incident akathisia using the Barnes Akathisia Scale and tardive dyskinesia was assessed using the Abnormal Involuntary Movement Scale. Changes in UKU measured at each visit. Metabolic labs assessed monthly. Attrition. Other adverse events self-reported throughout study participation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pharmacotherapy</title>
          <description>sertraline plus olanzapine</description>
        </group>
        <group group_id="E2">
          <title>Monotherapy</title>
          <description>placebo plus olanzapine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>broken hip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>knee sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>worsening depression</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>worsening symptoms of depression requiring (re)hospitalization</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>leg pain/edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>nausea/vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>sleepiness/sedation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>reduced sleep</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Increased fatigability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>increased sleep</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>increased dream activity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>dizziness/feeling faint</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>increased lab values</sub_title>
                <description>triglycerides, cholesterol, LFTs</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>akathisia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>pedal edema/edema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Barnett S. Meyers, MD</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>914-997-5721</phone>
      <email>bmeyers@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

